Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its ...

The rationale behind the treatment is that, because genetic FXI deficiency has been linked with reduced risk of ischemic ...

The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...

Bayer presents positive data on asundexian, which shows superior efficacy with no added bleeding risk, boosting hopes for ...

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic ...

In a U.S. ED observation TIA cohort, transthoracic echocardiography identified high risk cardioembolic features in nearly 1 in 5, most often patent foramen ovale and reduced LVEF.

A new predictive tool may help identify patients at risk for poststroke dementia, potentially accelerating research and ...

An investigational anti-clotting medication, asundexian, has demonstrated a reduction in the risk of a second ischemic ...

A recent observational study has highlighted the clinical value of transthoracic echocardiography (TTE) in patients evaluated ...

Global phase 3 OCEANIC-STROKE randomized 12,327 patients to asundexian 50 mg daily vs placebo on background antiplatelets, with follow-up to 31 months. Treatment effects were consistent across TOAST ...

Coronation Street has aired a devastating cliffhanger for Debbie Webster tonight, following her dramatic court sentencing.

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...